Potential conflict of interest: Nothing to report.
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin
Article first published online: 29 APR 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 59, Issue 6, pages 2101–2109, June 2014
How to Cite
Santantonio, T., Fasano, M., Sagnelli, E., Tundo, P., Babudieri, S., Fabris, P., Toti, M., Di Perri, G., Marino, N., Pizzigallo, E., Angarano, G. and the Acute Hepatitis C Study Group (2014), Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. Hepatology, 59: 2101–2109. doi: 10.1002/hep.26991
The study sponsor for drug supply and financial support was Schering-Plough (now Merck) SpA, Milan, Italy.
- Issue published online: 28 MAY 2014
- Article first published online: 29 APR 2014
- Accepted manuscript online: 18 JAN 2014 03:52AM EST
- Manuscript Accepted: 23 DEC 2013
- Manuscript Revised: 19 NOV 2013
- Manuscript Received: 6 SEP 2013
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.